|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BRWD1 |
Gene summary for BRWD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BRWD1 | Gene ID | 54014 |
| Gene name | bromodomain and WD repeat domain containing 1 | |
| Gene Alias | C21orf107 | |
| Cytomap | 21q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9NSI6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54014 | BRWD1 | HTA12-26-1 | Human | Pancreas | PDAC | 1.05e-10 | 7.56e-01 | 0.3728 |
| 54014 | BRWD1 | HTA12-29-1 | Human | Pancreas | PDAC | 5.24e-27 | 7.15e-01 | 0.3722 |
| 54014 | BRWD1 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 3.74e-02 | 1.11e-01 | -0.2126 |
| 54014 | BRWD1 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 1.09e-02 | 3.44e-01 | -0.2247 |
| 54014 | BRWD1 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 7.79e-09 | 3.01e-01 | -0.1833 |
| 54014 | BRWD1 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 1.70e-04 | 2.18e-01 | -0.23 |
| 54014 | BRWD1 | 047563_1562-all-cells | Human | Prostate | BPH | 9.62e-10 | 3.35e-01 | 0.0791 |
| 54014 | BRWD1 | 048752_1579-all-cells | Human | Prostate | BPH | 6.57e-32 | 5.05e-01 | 0.1008 |
| 54014 | BRWD1 | 052095_1628-all-cells | Human | Prostate | BPH | 3.72e-33 | 6.34e-01 | 0.1032 |
| 54014 | BRWD1 | 052097_1595-all-cells | Human | Prostate | BPH | 4.52e-34 | 6.99e-01 | 0.0972 |
| 54014 | BRWD1 | 052099_1652-all-cells | Human | Prostate | BPH | 8.00e-24 | 6.15e-01 | 0.1038 |
| 54014 | BRWD1 | Dong_P1 | Human | Prostate | Tumor | 3.27e-17 | 1.96e-02 | 0.035 |
| 54014 | BRWD1 | Dong_P3 | Human | Prostate | Tumor | 3.61e-09 | 6.63e-02 | 0.0278 |
| 54014 | BRWD1 | Dong_P4 | Human | Prostate | Tumor | 1.86e-04 | 4.57e-02 | 0.0292 |
| 54014 | BRWD1 | Dong_P5 | Human | Prostate | Tumor | 4.87e-11 | -5.65e-02 | 0.053 |
| 54014 | BRWD1 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 6.08e-05 | 5.47e-01 | 0.1557 |
| 54014 | BRWD1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.76e-07 | 5.58e-01 | 0.1633 |
| 54014 | BRWD1 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 9.32e-09 | 5.17e-01 | 0.1608 |
| 54014 | BRWD1 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 2.37e-06 | 6.08e-01 | 0.1604 |
| 54014 | BRWD1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 8.76e-05 | 5.09e-01 | 0.1621 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
| GO:00083608 | Cervix | CC | regulation of cell shape | 38/2311 | 154/18723 | 1.86e-05 | 3.46e-04 | 38 |
| GO:0022604 | Colorectum | AD | regulation of cell morphogenesis | 109/3918 | 309/18723 | 3.08e-09 | 2.07e-07 | 109 |
| GO:0008360 | Colorectum | AD | regulation of cell shape | 56/3918 | 154/18723 | 7.01e-06 | 1.73e-04 | 56 |
| GO:00226041 | Colorectum | SER | regulation of cell morphogenesis | 89/2897 | 309/18723 | 1.51e-09 | 1.52e-07 | 89 |
| GO:00083601 | Colorectum | SER | regulation of cell shape | 43/2897 | 154/18723 | 5.47e-05 | 1.30e-03 | 43 |
| GO:00226042 | Colorectum | MSS | regulation of cell morphogenesis | 103/3467 | 309/18723 | 2.70e-10 | 2.56e-08 | 103 |
| GO:00083602 | Colorectum | MSS | regulation of cell shape | 52/3467 | 154/18723 | 4.40e-06 | 1.24e-04 | 52 |
| GO:00226044 | Colorectum | FAP | regulation of cell morphogenesis | 87/2622 | 309/18723 | 4.89e-11 | 1.87e-08 | 87 |
| GO:00083603 | Colorectum | FAP | regulation of cell shape | 43/2622 | 154/18723 | 4.55e-06 | 1.52e-04 | 43 |
| GO:00226045 | Colorectum | CRC | regulation of cell morphogenesis | 74/2078 | 309/18723 | 9.25e-11 | 5.04e-08 | 74 |
| GO:00083604 | Colorectum | CRC | regulation of cell shape | 38/2078 | 154/18723 | 1.51e-06 | 8.15e-05 | 38 |
| GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
| GO:000836018 | Esophagus | ESCC | regulation of cell shape | 92/8552 | 154/18723 | 3.00e-04 | 1.81e-03 | 92 |
| GO:00226047 | Liver | NAFLD | regulation of cell morphogenesis | 62/1882 | 309/18723 | 8.35e-08 | 7.09e-06 | 62 |
| GO:00083606 | Liver | NAFLD | regulation of cell shape | 27/1882 | 154/18723 | 2.92e-03 | 2.65e-02 | 27 |
| GO:002260412 | Liver | Cirrhotic | regulation of cell morphogenesis | 127/4634 | 309/18723 | 1.45e-10 | 7.44e-09 | 127 |
| GO:000836012 | Liver | Cirrhotic | regulation of cell shape | 69/4634 | 154/18723 | 4.21e-08 | 1.36e-06 | 69 |
| GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
| GO:000836022 | Liver | HCC | regulation of cell shape | 92/7958 | 154/18723 | 1.15e-05 | 1.31e-04 | 92 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BRWD1 | SNV | Missense_Mutation | c.4784G>C | p.Arg1595Thr | p.R1595T | Q9NSI6 | protein_coding | tolerated(0.05) | benign(0.096) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| BRWD1 | SNV | Missense_Mutation | novel | c.3551N>G | p.Ala1184Gly | p.A1184G | Q9NSI6 | protein_coding | tolerated(0.1) | probably_damaging(0.926) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| BRWD1 | SNV | Missense_Mutation | c.5956N>C | p.Glu1986Gln | p.E1986Q | Q9NSI6 | protein_coding | deleterious_low_confidence(0.05) | benign(0.23) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| BRWD1 | SNV | Missense_Mutation | c.3436G>C | p.Glu1146Gln | p.E1146Q | Q9NSI6 | protein_coding | tolerated(0.21) | possibly_damaging(0.63) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| BRWD1 | SNV | Missense_Mutation | novel | c.2423N>T | p.Arg808Ile | p.R808I | Q9NSI6 | protein_coding | deleterious(0.01) | possibly_damaging(0.548) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BRWD1 | SNV | Missense_Mutation | c.3668N>G | p.Ser1223Cys | p.S1223C | Q9NSI6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0XR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| BRWD1 | SNV | Missense_Mutation | novel | c.614N>T | p.Ser205Leu | p.S205L | Q9NSI6 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| BRWD1 | SNV | Missense_Mutation | c.4949N>G | p.Ser1650Cys | p.S1650C | Q9NSI6 | protein_coding | tolerated(0.1) | possibly_damaging(0.87) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| BRWD1 | SNV | Missense_Mutation | c.5464N>G | p.Ser1822Ala | p.S1822A | Q9NSI6 | protein_coding | tolerated_low_confidence(0.61) | possibly_damaging(0.446) | TCGA-C8-A12W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| BRWD1 | SNV | Missense_Mutation | c.773N>T | p.Arg258Ile | p.R258I | Q9NSI6 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |